+Follow
CobyGoh
No personal profile
14
Follow
0
Followers
0
Topic
0
Badge
Posts
Hot
CobyGoh
2021-06-24
Like and comment. Thanks!
Sorry, the original content has been removed
CobyGoh
2021-06-24
Wow
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":3554850244776764,"uuid":"3554850244776764","gmtCreate":1592272756472,"gmtModify":1624100564224,"name":"CobyGoh","pinyin":"cobygoh","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/4015f04860b0250023603164d64596a8","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":14,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.03.30","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":126978287,"gmtCreate":1624543340549,"gmtModify":1703839897923,"author":{"id":"3554850244776764","authorId":"3554850244776764","name":"CobyGoh","avatar":"https://static.tigerbbs.com/4015f04860b0250023603164d64596a8","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks!","listText":"Like and comment. Thanks!","text":"Like and comment. Thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/126978287","repostId":"2145046194","repostType":4,"repost":{"id":"2145046194","pubTimestamp":1624540200,"share":"https://www.laohu8.com/m/news/2145046194?lang=&edition=full","pubTime":"2021-06-24 21:10","market":"us","language":"en","title":"3 Tech Stocks with 35% to 54% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2145046194","media":"Motley Fool","summary":"Talking heads like to point to \"expensive\" tech stocks, but analysts think these technology names are still materially undervalued.","content":"<p>Investors appear to have soured on tech stocks over the last few months. The prospect of higher inflation and a rotation to cheaper \"reopening\" plays have certainly hurt some of the very stocks that have powered the market's gains over the past few years.</p>\n<p>But digital trends aren't going away with the reopening, so if the world goes back to a pre-pandemic \"normal,\" it's reasonable to expect that technology stocks will eventually gain some market leadership and continue their strong relative performance. Today, Wall Street analysts see larger-than-average gains between 35% and 54% for the stocks of <b>Alteryx</b> (NYSE:AYX), <b>Uber Technologies</b> (NYSE:UBER), and <b>Micron Technology</b> (NASDAQ:MU).</p>\n<p><img src=\"https://static.tigerbbs.com/1459afd2cda964bb91343031338eaea0\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<h3>Alteryx: Implied upside of 35%</h3>\n<p>Data analytics software company Alteryx has not only seen its shares fall with its peer group in 2021, but it actually underperformed the sector in 2020 as well. Currently, the stock is down more than 50% from the all-time highs set back in July 2020, and it trades at just 11 times sales, a discount to most of its peers in the SaaS sector.</p>\n<p>There are a couple of reasons for Alteryx's relative underperformance. First, it has to use a strange accounting convention, whereby it recognizes 35%-40% of its contract value upfront, with the rest recognized ratably over time. That can really distort things when new business slows down, or when contract terms compress. That happened with the onset of the pandemic, so it appeared that Alteryx's revenue had plunged. However, its customer growth and annual recurring revenue (ARR), which aren't affected by accounting conventions, showed much stronger growth this past year:</p>\n<table>\n <thead>\n <tr>\n <th><p><b>Alteryx</b></p></th>\n <th><p><b>Q1 2020</b></p></th>\n <th><p><b>Q2 2020</b></p></th>\n <th><p><b>Q3 2020</b></p></th>\n <th><p><b>Q4 2020</b></p></th>\n <th><p><b>Q1 2021</b></p></th>\n </tr>\n </thead>\n <tbody>\n <tr>\n <td width=\"104\"><p>Revenue growth (YOY)</p></td>\n <td width=\"104\"><p>43%</p></td>\n <td width=\"104\"><p>17%</p></td>\n <td width=\"104\"><p>25%</p></td>\n <td width=\"104\"><p>3%</p></td>\n <td width=\"104\"><p>9%</p></td>\n </tr>\n <tr>\n <td width=\"104\"><p>ARR growth (YOY)</p></td>\n <td width=\"104\"><p>N/A</p></td>\n <td width=\"104\"><p>40%</p></td>\n <td width=\"104\"><p>38%</p></td>\n <td width=\"104\"><p>32%</p></td>\n <td width=\"104\"><p>27%</p></td>\n </tr>\n <tr>\n <td width=\"104\"><p>Customer growth (YOY)</p></td>\n <td width=\"104\"><p>30%</p></td>\n <td width=\"104\"><p>27%</p></td>\n <td width=\"104\"><p>24%</p></td>\n <td width=\"104\"><p>16%</p></td>\n <td width=\"104\"><p>12%</p></td>\n </tr>\n </tbody>\n</table>\n<p>Data source: Alteryx earnings transcripts. YOY = year over year.</p>\n<p>While there is some deceleration, it's somewhat inevitable that a company will decelerate as it grows. Moreover, new CEO Mark Anderson, who took over in late 2020, is fairly new to the job. He has taken a more focused approach to sales and marketing, concentrating Alteryx's efforts on the largest global companies with more capacity to spend. So that could be why the customer count is slowing -- Alteryx is implementing a strategy of getting its best customers to spend more. On the recent conference call with analysts, Anderson reiterated that he sees \"new and significant expansion opportunities,\" just within the Global 2000 large-cap companies, where Alteryx only has 39% penetration.</p>\n<p>Wall Street analysts appear to believe in Anderson, who has a track record of scaling software businesses, most recently at <b><a href=\"https://laohu8.com/S/PANW\">Palo Alto Networks</a></b> (NYSE:PANW). The average target among 14 analysts who cover Alteryx stock is $117.71, about 35% upside from current levels.</p>\n<h3>Uber Technologies: Implied upside of 40%</h3>\n<p>With the economic reopening at hand, analysts are also warming up to the world's leading ride-hailing business, Uber Technologies. Obviously, Uber's core ride-hailing business took a big hit during the pandemic; however, the company was able to maintain some level of revenue stability thanks to its food delivery business, which skyrocketed with people stuck at home.</p>\n<p>Food delivery revenue rose 230% last quarter, helped out by the December acquisition of Postmates and helping to offset a 41% year-over-year decline in mobility revenue. Last quarter, food delivery was actually the largest segment by revenue for the first time. Helped out by increased operating leverage, higher take rates, and cost cuts following the Postmates acquisition, Uber's food delivery platform saw adjusted EBITDA losses narrow from $313 million to $200 million last quarter. On the conference call with analysts, CEO Dara Khosrowshahi said he expects EBITDA breakeven for the delivery business by year end. The freight business also continued to grow nicely, with revenue up 51% and EBITDA losses improving by 55%.</p>\n<p>Uber has also been streamlining its business, selling off its autonomous vehicle and flying car divisions to start-ups, and management expects the streamlining of the business will lead to profitability in the near term -- at least on an adjusted EBITDA basis.</p>\n<p>The ideal scenario would be for food delivery revenue to stick around due to new habits and work-from-anywhere cultures, with ride-sharing bouncing back strongly and the freight business scaling. Analysts appear to share the sunny outlook, with the average price target among 38 analysts at $68.64, about 40% above current stock levels.</p>\n<h3>Micron Technology: Implied upside of 53.6%</h3>\n<p>Finally, memory chip maker Micron Technology also has lots of upside, according to Wall Street analysts. It may be surprising that Micron is down some 21% from all-time highs, given that memory prices have been rising amid a big chip shortage. Perhaps Micron's participation in the technology sector has contributed to the skepticism.</p>\n<p>What's strange is that Micron, unlike a lot of high-growth software stocks, is really more like a cyclical stock, and appears set for higher profits throughout 2021 and into 2022. In fact, the stock only trades at a mere 7.5 times next year's earnings estimates. Micron has also committed to return at least 50% of free cash flow to shareholders via share repurchases, so the company will likely take advantage of the currently discounted stock price by buying back stock.</p>\n<p>Of course, Micron's share price is quite volatile, so investors should be prepared. Some analysts appear to be looking for the next down cycle, as Micron tends to boom and bust based on memory prices. In fact, <a href=\"https://laohu8.com/S/AONE\">one</a> analyst at Lynx Equity Strategies just downgraded Micron to a sell rating based on the anticipation of memory price slowdowns in the back half of the year; but strangely, that same analyst lowered his price target from $110 to $100, still about 30% higher than today's stock price!</p>\n<p>Fears of a downturn seem a bit premature to me, since memory cycles tend to last a couple years, not just two good quarters. Micron remained profitable in the recent downturn, and could potentially make higher highs in this up cycle. Meanwhile, memory-intensive digitization trends around 5G, AI, and the Internet of Things accelerated during the pandemic, which I wouldn't expect to slow down any time soon.</p>\n<p>Most analysts appear to have a more bullish outlook, with the average price target among 30 analysts covering the stock at $118.62, about 53% higher than the price today. In fact, even the lowest analyst price target is $90, about 18% higher than the current stock price, and the highest price target is $172. With a single-digit P/E ratio and that kind of discount, Micron looks like an intriguing tech play for value investors.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Tech Stocks with 35% to 54% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Tech Stocks with 35% to 54% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 21:10 GMT+8 <a href=https://www.fool.com/investing/2021/06/24/3-tech-stocks-with-35-to-54-upside/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors appear to have soured on tech stocks over the last few months. The prospect of higher inflation and a rotation to cheaper \"reopening\" plays have certainly hurt some of the very stocks that ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/24/3-tech-stocks-with-35-to-54-upside/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MU":"美光科技","UBER":"优步","AYX":"Alteryx Inc."},"source_url":"https://www.fool.com/investing/2021/06/24/3-tech-stocks-with-35-to-54-upside/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145046194","content_text":"Investors appear to have soured on tech stocks over the last few months. The prospect of higher inflation and a rotation to cheaper \"reopening\" plays have certainly hurt some of the very stocks that have powered the market's gains over the past few years.\nBut digital trends aren't going away with the reopening, so if the world goes back to a pre-pandemic \"normal,\" it's reasonable to expect that technology stocks will eventually gain some market leadership and continue their strong relative performance. Today, Wall Street analysts see larger-than-average gains between 35% and 54% for the stocks of Alteryx (NYSE:AYX), Uber Technologies (NYSE:UBER), and Micron Technology (NASDAQ:MU).\n\nImage source: Getty Images.\nAlteryx: Implied upside of 35%\nData analytics software company Alteryx has not only seen its shares fall with its peer group in 2021, but it actually underperformed the sector in 2020 as well. Currently, the stock is down more than 50% from the all-time highs set back in July 2020, and it trades at just 11 times sales, a discount to most of its peers in the SaaS sector.\nThere are a couple of reasons for Alteryx's relative underperformance. First, it has to use a strange accounting convention, whereby it recognizes 35%-40% of its contract value upfront, with the rest recognized ratably over time. That can really distort things when new business slows down, or when contract terms compress. That happened with the onset of the pandemic, so it appeared that Alteryx's revenue had plunged. However, its customer growth and annual recurring revenue (ARR), which aren't affected by accounting conventions, showed much stronger growth this past year:\n\n\n\nAlteryx\nQ1 2020\nQ2 2020\nQ3 2020\nQ4 2020\nQ1 2021\n\n\n\n\nRevenue growth (YOY)\n43%\n17%\n25%\n3%\n9%\n\n\nARR growth (YOY)\nN/A\n40%\n38%\n32%\n27%\n\n\nCustomer growth (YOY)\n30%\n27%\n24%\n16%\n12%\n\n\n\nData source: Alteryx earnings transcripts. YOY = year over year.\nWhile there is some deceleration, it's somewhat inevitable that a company will decelerate as it grows. Moreover, new CEO Mark Anderson, who took over in late 2020, is fairly new to the job. He has taken a more focused approach to sales and marketing, concentrating Alteryx's efforts on the largest global companies with more capacity to spend. So that could be why the customer count is slowing -- Alteryx is implementing a strategy of getting its best customers to spend more. On the recent conference call with analysts, Anderson reiterated that he sees \"new and significant expansion opportunities,\" just within the Global 2000 large-cap companies, where Alteryx only has 39% penetration.\nWall Street analysts appear to believe in Anderson, who has a track record of scaling software businesses, most recently at Palo Alto Networks (NYSE:PANW). The average target among 14 analysts who cover Alteryx stock is $117.71, about 35% upside from current levels.\nUber Technologies: Implied upside of 40%\nWith the economic reopening at hand, analysts are also warming up to the world's leading ride-hailing business, Uber Technologies. Obviously, Uber's core ride-hailing business took a big hit during the pandemic; however, the company was able to maintain some level of revenue stability thanks to its food delivery business, which skyrocketed with people stuck at home.\nFood delivery revenue rose 230% last quarter, helped out by the December acquisition of Postmates and helping to offset a 41% year-over-year decline in mobility revenue. Last quarter, food delivery was actually the largest segment by revenue for the first time. Helped out by increased operating leverage, higher take rates, and cost cuts following the Postmates acquisition, Uber's food delivery platform saw adjusted EBITDA losses narrow from $313 million to $200 million last quarter. On the conference call with analysts, CEO Dara Khosrowshahi said he expects EBITDA breakeven for the delivery business by year end. The freight business also continued to grow nicely, with revenue up 51% and EBITDA losses improving by 55%.\nUber has also been streamlining its business, selling off its autonomous vehicle and flying car divisions to start-ups, and management expects the streamlining of the business will lead to profitability in the near term -- at least on an adjusted EBITDA basis.\nThe ideal scenario would be for food delivery revenue to stick around due to new habits and work-from-anywhere cultures, with ride-sharing bouncing back strongly and the freight business scaling. Analysts appear to share the sunny outlook, with the average price target among 38 analysts at $68.64, about 40% above current stock levels.\nMicron Technology: Implied upside of 53.6%\nFinally, memory chip maker Micron Technology also has lots of upside, according to Wall Street analysts. It may be surprising that Micron is down some 21% from all-time highs, given that memory prices have been rising amid a big chip shortage. Perhaps Micron's participation in the technology sector has contributed to the skepticism.\nWhat's strange is that Micron, unlike a lot of high-growth software stocks, is really more like a cyclical stock, and appears set for higher profits throughout 2021 and into 2022. In fact, the stock only trades at a mere 7.5 times next year's earnings estimates. Micron has also committed to return at least 50% of free cash flow to shareholders via share repurchases, so the company will likely take advantage of the currently discounted stock price by buying back stock.\nOf course, Micron's share price is quite volatile, so investors should be prepared. Some analysts appear to be looking for the next down cycle, as Micron tends to boom and bust based on memory prices. In fact, one analyst at Lynx Equity Strategies just downgraded Micron to a sell rating based on the anticipation of memory price slowdowns in the back half of the year; but strangely, that same analyst lowered his price target from $110 to $100, still about 30% higher than today's stock price!\nFears of a downturn seem a bit premature to me, since memory cycles tend to last a couple years, not just two good quarters. Micron remained profitable in the recent downturn, and could potentially make higher highs in this up cycle. Meanwhile, memory-intensive digitization trends around 5G, AI, and the Internet of Things accelerated during the pandemic, which I wouldn't expect to slow down any time soon.\nMost analysts appear to have a more bullish outlook, with the average price target among 30 analysts covering the stock at $118.62, about 53% higher than the price today. In fact, even the lowest analyst price target is $90, about 18% higher than the current stock price, and the highest price target is $172. With a single-digit P/E ratio and that kind of discount, Micron looks like an intriguing tech play for value investors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128609873,"gmtCreate":1624512126192,"gmtModify":1703838916850,"author":{"id":"3554850244776764","authorId":"3554850244776764","name":"CobyGoh","avatar":"https://static.tigerbbs.com/4015f04860b0250023603164d64596a8","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128609873","repostId":"2145501913","repostType":4,"repost":{"id":"2145501913","pubTimestamp":1624495680,"share":"https://www.laohu8.com/m/news/2145501913?lang=&edition=full","pubTime":"2021-06-24 08:48","market":"us","language":"en","title":"Monte Rosa Therapeutics Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2145501913","media":"StreetInsider","summary":"BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnol","content":"<p>BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a>, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins, today announced the pricing of its initial public offering of 11,700,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Monte Rosa. The shares are expected to begin trading on the Nasdaq Global Select Market on June 24, 2021 under the ticker symbol “GLUE.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Monte Rosa, are expected to be approximately $222.3 million. The offering is expected to close on June 28, 2021, subject to the satisfaction of customary closing conditions. In addition, Monte Rosa has granted the underwriters a 30-day option to purchase up to an additional 1,755,000 shares of common stock at the initial public offering price.</p>\n<p>J.P. Morgan Securities LLC, Cowen, Piper Sandler and Guggenheim Securities, LLC are acting as joint book-running managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 23, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone at (866) 803-9204, or via email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or via email: prospectus@psc.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at gsequityprospectusdelivery@guggenheimpartners.com.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><b>About Monte Rosa</b></p>\n<p>Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™, that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Therapeutics Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Therapeutics Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 08:48 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=18597450><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18597450\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLUE":"Monte Rosa Therapeutics"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18597450","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145501913","content_text":"BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins, today announced the pricing of its initial public offering of 11,700,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Monte Rosa. The shares are expected to begin trading on the Nasdaq Global Select Market on June 24, 2021 under the ticker symbol “GLUE.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Monte Rosa, are expected to be approximately $222.3 million. The offering is expected to close on June 28, 2021, subject to the satisfaction of customary closing conditions. In addition, Monte Rosa has granted the underwriters a 30-day option to purchase up to an additional 1,755,000 shares of common stock at the initial public offering price.\nJ.P. Morgan Securities LLC, Cowen, Piper Sandler and Guggenheim Securities, LLC are acting as joint book-running managers for the offering.\nA registration statement relating to these securities became effective on June 23, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone at (866) 803-9204, or via email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or via email: prospectus@psc.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at gsequityprospectusdelivery@guggenheimpartners.com.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Monte Rosa\nMonte Rosa Therapeutics is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™, that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.","news_type":1},"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":126978287,"gmtCreate":1624543340549,"gmtModify":1703839897923,"author":{"id":"3554850244776764","authorId":"3554850244776764","name":"CobyGoh","avatar":"https://static.tigerbbs.com/4015f04860b0250023603164d64596a8","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Like and comment. Thanks!","listText":"Like and comment. Thanks!","text":"Like and comment. Thanks!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/126978287","repostId":"2145046194","repostType":4,"isVote":1,"tweetType":1,"viewCount":164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":128609873,"gmtCreate":1624512126192,"gmtModify":1703838916850,"author":{"id":"3554850244776764","authorId":"3554850244776764","name":"CobyGoh","avatar":"https://static.tigerbbs.com/4015f04860b0250023603164d64596a8","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/128609873","repostId":"2145501913","repostType":4,"repost":{"id":"2145501913","pubTimestamp":1624495680,"share":"https://www.laohu8.com/m/news/2145501913?lang=&edition=full","pubTime":"2021-06-24 08:48","market":"us","language":"en","title":"Monte Rosa Therapeutics Announces Pricing of Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2145501913","media":"StreetInsider","summary":"BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnol","content":"<p>BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- <a href=\"https://laohu8.com/S/GLUE\">Monte Rosa Therapeutics</a>, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins, today announced the pricing of its initial public offering of 11,700,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Monte Rosa. The shares are expected to begin trading on the Nasdaq Global Select Market on June 24, 2021 under the ticker symbol “GLUE.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Monte Rosa, are expected to be approximately $222.3 million. The offering is expected to close on June 28, 2021, subject to the satisfaction of customary closing conditions. In addition, Monte Rosa has granted the underwriters a 30-day option to purchase up to an additional 1,755,000 shares of common stock at the initial public offering price.</p>\n<p>J.P. Morgan Securities LLC, Cowen, Piper Sandler and Guggenheim Securities, LLC are acting as joint book-running managers for the offering.</p>\n<p>A registration statement relating to these securities became effective on June 23, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone at (866) 803-9204, or via email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or via email: prospectus@psc.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at gsequityprospectusdelivery@guggenheimpartners.com.</p>\n<p>This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>\n<p><b>About Monte Rosa</b></p>\n<p>Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™, that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Monte Rosa Therapeutics Announces Pricing of Initial Public Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMonte Rosa Therapeutics Announces Pricing of Initial Public Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-24 08:48 GMT+8 <a href=https://www.streetinsider.com/dr/news.php?id=18597450><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=18597450\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GLUE":"Monte Rosa Therapeutics"},"source_url":"https://www.streetinsider.com/dr/news.php?id=18597450","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2145501913","content_text":"BOSTON, June 23, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins, today announced the pricing of its initial public offering of 11,700,000 shares of common stock at a public offering price of $19.00 per share. All of the shares are being offered by Monte Rosa. The shares are expected to begin trading on the Nasdaq Global Select Market on June 24, 2021 under the ticker symbol “GLUE.” The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Monte Rosa, are expected to be approximately $222.3 million. The offering is expected to close on June 28, 2021, subject to the satisfaction of customary closing conditions. In addition, Monte Rosa has granted the underwriters a 30-day option to purchase up to an additional 1,755,000 shares of common stock at the initial public offering price.\nJ.P. Morgan Securities LLC, Cowen, Piper Sandler and Guggenheim Securities, LLC are acting as joint book-running managers for the offering.\nA registration statement relating to these securities became effective on June 23, 2021. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, Attn: Prospectus Department, 1155 Long Island Avenue, Edgewood, New York 11717, via telephone at (866) 803-9204, or via email at prospectus-eq_fi@jpmchase.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926; Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or via email: prospectus@psc.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-5548, or by email at gsequityprospectusdelivery@guggenheimpartners.com.\nThis press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.\nAbout Monte Rosa\nMonte Rosa Therapeutics is a biotechnology company developing a portfolio of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™, that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.","news_type":1},"isVote":1,"tweetType":1,"viewCount":181,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
